{"id":"racemic-albuterol-mdi","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Tremor"},{"rate":"5-10","effect":"Headache"},{"rate":"3-8","effect":"Nervousness"},{"rate":"2-5","effect":"Palpitations"},{"rate":"2-5","effect":"Tachycardia"},{"rate":"1-3","effect":"Muscle cramps"}]},"_chembl":{"chemblId":"CHEMBL1441059","moleculeType":"Small molecule","molecularWeight":"576.71"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Albuterol binds to beta-2 adrenergic receptors on airway smooth muscle cells, activating intracellular signaling that increases cAMP levels and causes smooth muscle relaxation. This bronchodilation effect provides rapid relief of airway obstruction and improved breathing. The racemic formulation contains both R- and S-enantiomers, though the R-enantiomer is the pharmacologically active form.","oneSentence":"Racemic albuterol is a beta-2 adrenergic agonist that relaxes airway smooth muscle to relieve bronchospasm and improve airflow in obstructive airway diseases.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:52:10.977Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute bronchospasm relief in asthma"},{"name":"Chronic obstructive pulmonary disease (COPD) maintenance and acute symptom relief"}]},"trialDetails":[{"nctId":"NCT01656811","phase":"PHASE2","title":"A Study of Daily Dosing With Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects With Asthma","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2001-10","conditions":"Asthma","enrollment":146},{"nctId":"NCT00073814","phase":"PHASE3","title":"Study of Daily Dosing With Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects With Asthma","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2002-12","conditions":"Asthma","enrollment":80},{"nctId":"NCT00685347","phase":"PHASE2","title":"Dose Response Study of Levalbuterol in the Prevention of Exercise Induced Bronchoconstriction Compared to Racemic Albuterol in Pediatric Subjects","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2003-01","conditions":"Asthma, Bronchoconstriction","enrollment":33},{"nctId":"NCT00684866","phase":"PHASE2","title":"Safety and Tolerability Study of Levalbuterol HFA and Racemic Albuterol HFA in Pediatrics Subjects With Asthma","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2003-01","conditions":"Asthma","enrollment":31},{"nctId":"NCT00685022","phase":"PHASE2","title":"Safety and Tolerability Study of Levalbuterol HFA Compared to Racemic Albuterol HFA in Subjects With Asthma","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2003-06","conditions":"Asthma","enrollment":49},{"nctId":"NCT00684827","phase":"PHASE2","title":"A Safety and Tolerability Study of Levalbuterol HFA Metered Dose Inhaler in Subjects With Asthma","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2002-10","conditions":"Asthma","enrollment":32},{"nctId":"NCT00064389","phase":"PHASE3","title":"Long Term Safety Study of Levalbuterol and Racemic Albuterol in Subjects Twelve Years of Age and Older With Asthma","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2003-01","conditions":"Asthma","enrollment":746},{"nctId":"NCT00073827","phase":"PHASE3","title":"Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2002-05","conditions":"Asthma","enrollment":445},{"nctId":"NCT00064415","phase":"PHASE3","title":"To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2002-06","conditions":"Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema","enrollment":799},{"nctId":"NCT00685425","phase":"PHASE3","title":"Dose Response Study of Levalbuterol in the Prevention of Exercise Induced Bronchoconstriction Compared to Racemic Albuterol","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2002-10","conditions":"Asthma, Bronchoconstriction","enrollment":62}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"racemic albuterol MDI","genericName":"racemic albuterol MDI","companyName":"Sumitomo Pharma America, Inc.","companyId":"sumitomo-pharma-america-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Racemic albuterol is a beta-2 adrenergic agonist that relaxes airway smooth muscle to relieve bronchospasm and improve airflow in obstructive airway diseases. Used for Acute bronchospasm relief in asthma, Chronic obstructive pulmonary disease (COPD) maintenance and acute symptom relief.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}